SEC 13F Intelligence

Avidity Partners Management LP / REGN

Avidity Partners Management LP’s Regeneron Pharmaceuticals Position

Does Avidity Partners Management LP own Regeneron Pharmaceuticals (REGN)? Not currently — the last reported position was 25.4K shares worth $16M in Q1 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$16M
Q1 2025
Shares
25.4K
% of Portfolio
+3.07%
Quarters Held
10
position exited

Position History REGN

Reported value by quarter
Q2 ’20: $82MQ2 ’20Q3 ’21: $92MQ1 ’23: $98MQ1 ’23Q2 ’23: $18MQ3 ’23: $48MQ3 ’23Q4 ’23: $60MQ1 ’24: $65MQ1 ’24Q2 ’24: $50MQ4 ’24: $6MQ4 ’24Q1 ’25: $16Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202525.4K$16M+3.07%
Q4 20248.4K$6M+0.59%
Q2 202448.0K$50M+2.14%
Q1 202468.0K$65M+2.11%
Q4 202368.0K$60M+2.18%
Q3 202358.0K$48M+1.92%
Q2 202324.8K$18M+0.62%
Q1 2023119.1K$98M+3.25%
Q3 2021152.3K$92M+2.04%
Q2 2020132.1K$82M+5.28%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Avidity Partners Management LP’s full portfolio or all institutional holders of REGN.